{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T16:15:23Z","timestamp":1790612123637,"version":"4.1.0"},"reference-count":26,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T00:00:00Z","timestamp":1703116800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>Although statins are often discontinued when myalgia arises, a causal relationship may not always exist. How well-tolerated statins are when rechallenge is blinded and controlled is unclear.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods and findings<\/jats:title>\n<jats:p>We performed a systematic review and meta-analysis (PROSPERO CRD42023437648) to evaluate the success of statin rechallenge versus matched placebo in those who were previously statin intolerant. Our primary outcome was intolerance; our secondary outcome was the myalgia or global symptom score. Medline, Embase, CINAHL Plus, Scopus, and CENTRAL were searched from inception to May 1, 2023. Eligible trials were randomized controlled trials with parallel or crossover designs examining statin rechallenge in statin-intolerant adults. Two independent reviewers selected studies, extracted data, and assessed risk of bias (Cochrane Collaboration\u2019s risk-of-bias tool 1). Relative risk (RR) and mean difference (MD) were estimated using fixed effect Mantel-Haenszel statistics. Of 1,941 studies screened, 8 met our inclusion criteria (8 to 491 participants from Asia, Europe, North America, and Oceana). Compared to placebo, intolerance was more common in statin users [325\/906 (36%) vs 233\/911 (26%), RR 1.40, 95% CI, 1.23 to 1.60, I<jats:sup>2<\/jats:sup> = 0%, 7 trials, number needed to harm 10] and there was no statistically significant difference in myalgia or global symptom score on a 100-point scale [MD 1.08, 95% CI, -1.51 to 3.67, I<jats:sup>2<\/jats:sup> = 0%, 5 trials]. Limitations include only 1 trial asking participants about intolerable symptoms (vs inferring intolerance from discontinuation or trial withdrawal); the small number of trials; the possibility of attrition bias; and the potential for carryover effects in crossover\/n-of-1 trial designs.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Of those previously intolerant of statins who were rechallenged with a statin and compared to placebo recipients, medication intolerance was more common amongst statin recipients. However, there was no significant difference in mean myalgia or global symptom score between statin and placebo, and only one-third of those previously believed to be statin intolerant were unable to tolerate a statin on blinded rechallenge; one-quarter were intolerant of placebo.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0295857","type":"journal-article","created":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T18:38:15Z","timestamp":1703183895000},"page":"e0295857","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":7,"title":["Intolerance upon statin rechallenge: A systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.1371","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3354-4955","authenticated-orcid":true,"given":"Roni","family":"Kraut","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faith","family":"Wierenga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Molstad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Korownyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Perry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liz","family":"Dennett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Garrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2023,12,21]]},"reference":[{"key":"pone.0295857.ref001","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"F Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"pone.0295857.ref002","first-page":"e596","article-title":"2019 ACC\/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"140","author":"DK Arnett","year":"2019","journal-title":"Circulation"},{"key":"pone.0295857.ref003","doi-asserted-by":"crossref","first-page":"675","DOI":"10.46747\/cfp.6910675","article-title":"PEER simplified lipid guideline 2023 update: Prevention and management of cardiovascular disease in primary care","volume":"69","author":"MR Kolber","year":"2023","journal-title":"Can Fam Physician"},{"key":"pone.0295857.ref004","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.1093\/eurheartj\/ehac015","article-title":"Prevalence of statin intolerance: a meta-analysis","volume":"43","author":"I Byty\u00e7i","year":"2022","journal-title":"Eur Heart J"},{"key":"pone.0295857.ref005","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1016\/j.jacc.2021.07.022","article-title":"Side Effect Patterns in a Crossover Trial of Statin, Placebo, and No Treatment","volume":"78","author":"JP Howard","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"pone.0295857.ref006","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1002\/jcsm.12344","article-title":"Introducing the \u2018Drucebo\u2019 effect in statin therapy: a systematic review of studies comparing reported rates of statin-associated muscle symptoms, under blinded and open-label conditions","volume":"9","author":"PE Penson","year":"2018","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"pone.0295857.ref007","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"PRISMA Group","year":"2009","journal-title":"PLoS Med"},{"key":"pone.0295857.ref008","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1002\/phar.2681","article-title":"Statin-associated muscle symptoms-A review: Individualizing the approach to optimize care","volume":"42","author":"BS Wiggins","year":"2022","journal-title":"Pharmacotherapy"},{"key":"pone.0295857.ref009","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1136\/emj.18.3.205","article-title":"The minimum clinically significant difference in visual analogue scale pain score does not differ with severity of pain","volume":"18","author":"AM Kelly","journal-title":"Emerg Med J. 200"},{"key":"pone.0295857.ref010","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane","author":"JPT Higgins","year":"2017"},{"key":"pone.0295857.ref011","volume-title":"Review Manager (RevMan), version 5.3 [software]","year":"2014"},{"key":"pone.0295857.ref012","doi-asserted-by":"crossref","first-page":"n135","DOI":"10.1136\/bmj.n135","article-title":"StatinWISE Trial Group. Statin treatment and muscle symptoms: series of randomised, placebo controlled n-of-1 trials","volume":"372","author":"E Herrett","year":"2021","journal-title":"BMJ"},{"key":"pone.0295857.ref013","first-page":"301","article-title":"N-of-1 (single-patient) trials for statin-related myalgia","volume":"160","author":"TR Joy","year":"2014","journal-title":"Ann Intern Med"},{"key":"pone.0295857.ref014","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.jacl.2011.03.454","article-title":"Efficacy and tolerability of once-weekly rosuvastatin in patients with previous statin intolerance","volume":"5","author":"SP Kennedy","year":"2011","journal-title":"J Clin Lipidol"},{"key":"pone.0295857.ref015","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1093\/ehjcvp\/pvaa076","article-title":"Effect of atorvastatin on muscle symptoms in coronary heart disease patients with self-perceived statin muscle side effects: a randomized, double-blinded crossover trial","volume":"7","author":"O Kristiansen","year":"2021","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"pone.0295857.ref016","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1001\/jama.2016.3608","article-title":"GAUSS-3 Investigators. Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial","volume":"315","author":"SE Nissen","year":"2016","journal-title":"JAMA"},{"key":"pone.0295857.ref017","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.amjcard.2007.09.099","article-title":"Efficacy and tolerability of fluvastatin XL 80 mg alone, ezetimibe alone, and the combination of fluvastatin XL 80 mg with ezetimibe in patients with a history of muscle-related side effects with other statins","volume":"101","author":"EA Stein","year":"2008","journal-title":"Am J Cardiol"},{"key":"pone.0295857.ref018","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.atherosclerosis.2014.12.016","article-title":"A randomized trial of coenzyme Q10 in patients with confirmed statin myopathy","volume":"238","author":"BA Taylor","year":"2015","journal-title":"Atherosclerosis"},{"key":"pone.0295857.ref019","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/j.jacl.2014.03.004","article-title":"The National Lipid Association\u2019s Muscle Safety Expert Panel. An assessment by the Statin Muscle Safety Task Force: 2014 update","volume":"8","author":"RS Rosenson","year":"2014","journal-title":"J Clin Lipidol"},{"key":"pone.0295857.ref020","first-page":"41","article-title":"Efficacy and Tolerability of non-daily Statin Administration: A Systematic Review of Literature","volume":"66","author":"C Park","year":"2019","journal-title":"J. Pharm. Pract"},{"key":"pone.0295857.ref021","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1001\/jama.2014.8342","article-title":"Avoiding nocebo effects to optimize treatment outcome","volume":"312","author":"Placebo Competence Team","year":"2014","journal-title":"JAMA"},{"key":"pone.0295857.ref022","doi-asserted-by":"crossref","first-page":"e007793","DOI":"10.1161\/CIRCOUTCOMES.120.007793","article-title":"Unblinded and Blinded N-of-1 Trials Versus Usual Care: A Randomized Controlled Trial to Increase Statin Uptake in Primary Care","volume":"15","author":"K Tudor","year":"2022","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"pone.0295857.ref023","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1517\/14740338.2012.712959","article-title":"Statin drug interactions and related adverse reactions","volume":"11","author":"S Bellosta","year":"2012","journal-title":"Expert Opin Drug Saf"},{"key":"pone.0295857.ref024","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1001\/archinte.165.22.2671","article-title":"Outcomes in 45 patients with statin-associated myopathy","volume":"165","author":"KE Hansen","year":"2005","journal-title":"Arch Intern Med"},{"key":"pone.0295857.ref025","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/CND.0b013e3182852558","article-title":"Outcomes of statin myopathy after statin withdrawal","volume":"14","author":"R Armour","year":"2013","journal-title":"J Clin Neuromuscul Dis"},{"key":"pone.0295857.ref026","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1592\/phco.30.6.541","article-title":"Statin-associated muscle-related adverse effects: a case series of 354 patients","volume":"30","author":"S Cham","year":"2010","journal-title":"Pharmacotherapy"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0295857","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T18:38:40Z","timestamp":1703183920000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0295857"}},"subtitle":[],"editor":[{"given":"Vikramaditya","family":"Samala Venkata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2023,12,21]]},"references-count":26,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2023,12,21]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0295857","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,21]]}}}